A Phase 1/2 interventional study of SAD: 30mg WVE-003 and SAD: 60mg WVE-003 in Huntington Disease, sponsored by Wave Life Sciences USA, Inc.. Completed at 23 sites in 10 countries. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Wave Life Sciences USA, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Huntington Disease with a site in United Kingdom — 10 open to participants now, 15 under way, 3 of them phase 3. Huntington Disease · United Kingdom.
Among the 51 studies in Huntington Disease with a site in United Kingdom, this one is the 25th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 1/2, and was the 32nd registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →10 of the 51 studies in Huntington Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Prilenia · Sites in United Kingdom, United States, Belgium and 9 more countries
Ages 23–65
Sarepta Therapeutics, Inc. · Sites in United Kingdom, Australia, New Zealand and 2 more countries
Ages 21–70
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United Kingdom, United States, Argentina and 7 more countries
Ages 25+
Alnylam Pharmaceuticals · Sites in United Kingdom, Canada, Germany
Ages 25–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 25 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 8
First in 2004; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 92 across the 38 interventional studies, 154 across the 13 observational. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 51 have an industry lead sponsor. The 10 most frequent:
Wave Life Sciences USA, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Wave Life Sciences USA, Inc. has 3 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Huntington Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246941Hoffmann-La RocheA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease | 2026-12-01 |
| NCT02855476University College, LondonHDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease | 2027-04-30 |
| NCT03434548King's College LondonIMarkHD: in Vivo Longitudinal Imaging of HD Pathology | 2027-06-30 |
| NCT07536061Sarepta Therapeutics, Inc.A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies in Huntington Disease with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Received any other study drug, including an oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer, with the exception of the following:
a. Received WVE-120101 or WVE-120102 within the last 3 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: SAD: Pooled Placebo
Single Ascending Dose - 30mg WVE-003
Drug: SAD: 30mg WVE-003
Single Ascending Dose - 60mg WVE-003
Drug: SAD: 60mg WVE-003
Single Ascending Dose - 90mg WVE-003
Drug: SAD: 90mg WVE-003
Placebo
Drug: MD: Placebo
Multiple Dose - 30mg WVE-003
Drug: MD: 30mg WVE-003
Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
Single dose of placebo
Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure, antisense oligonucleotide (ASO)
Three doses of placebo Q8WK
Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.
Time frame: Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)
Pharmacokinetics of WVE-003 in Plasma
Parameter analyzed: AUC0-6 = area under the concentration-time curve from time 0 to 6 hrs
Time frame: Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)
Pharmacokinetics of WVE-003 in Plasma
Parameter analyzed: Cmax = maximum observed concentration.
Time frame: Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)
Concentration of WVE-003 in Cerebrospinal Fluid (CSF)
WVE-003 concentration in cerebrospinal fluid (CSF) is reported in ng/mL.
Time frame: 28 days post-dose during Period 1 (P1:Day29); 28 days post last dose during Period 2 (P2: Day141)
| Milestone | SAD: Pooled Placebo | SAD: 30mg WVE-003* | SAD: 60mg WVE-003* | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 |
|---|---|---|---|---|---|---|
| Started | 16 | 12 | 11 | 8 | 0 | 0 |
| Completed | 16 | 11 | 11 | 7 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | SAD: Pooled Placebo | SAD: 30mg WVE-003* | SAD: 60mg WVE-003* | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 7 | 16 |
| Treated | 0 | 0 | 0 | 0 | 7 | 16 |
| Completed | 0 | 0 | 0 | 0 | 6 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.
| Participants | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 |
|---|---|---|---|---|---|---|
| Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug | 2 | 1 | 3 | 3 | 0 | 8 |
Parameter analyzed: AUC0-6 = area under the concentration-time curve from time 0 to 6 hrs
| AUC 0-6 (hr*ng/mL) | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: 30mg WVE-003 |
|---|---|---|---|---|
| D1: AUC 0-6 (hr*ng/mL) | 1000 ± 702 | 2310 ± 3090 | 3890 ± 2900 | 822 ± 409 |
| D113: AUC 0-6 (hr*ng/mL) | — | — | — | 698 ± 432 |
Parameter analyzed: Cmax = maximum observed concentration.
| Cmax (ng/mL) | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: 30mg WVE-003 |
|---|---|---|---|---|
| D1: Cmax (ng/mL) | 240 ± 168 | 601 ± 774 | 1061 ± 942 | 186 ± 106 |
| D113: Cmax (ng/mL) | — | — | — | 157 ± 97.3 |
WVE-003 concentration in cerebrospinal fluid (CSF) is reported in ng/mL.
| ng/mL | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: 30mg WVE-003 |
|---|---|---|---|---|
| Concentration of WVE-003 in Cerebrospinal Fluid (CSF) | 3.6405 ± 1.6133 | 5.5346 ± 2.8402 | 7.0983 ± 3.1335 | 4.2903 ± 1.9722 |
Collected over Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAD: Pooled Placebo | 0/16 (0%) | 1/16 (6.3%) | 13/16 (81.3%) |
| SAD: 30mg WVE-003 | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| SAD: 60mg WVE-003 | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| SAD: 90mg WVE-003 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| MD: Placebo | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| MD: 30mg WVE-003 | 0/16 (0%) | 0/16 (0%) | 13/16 (81.3%) |
| Event | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 |
|---|---|---|---|---|---|---|
| AtaxiaNervous system disorders | 0/16 | 0/13 | 1/10 | 0/8 | 0/7 | 0/16 |
| Post lumbar puncture syndromeInjury, poisoning and procedural complications | 1/16 | 0/13 | 0/10 | 0/8 | 0/7 | 0/16 |
| Event | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/16 | 4/13 | 2/10 | 4/8 | 3/7 | 4/16 |
| FallInjury, poisoning and procedural complications | 1/16 | 0/13 | 1/10 | 3/8 | 2/7 | 2/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 | 3/13 | 2/10 | 1/8 | 2/7 | 0/16 |
| Post lumbar puncture syndromeInjury, poisoning and procedural complications | 2/16 | 1/13 | 1/10 | 2/8 | 1/7 | 0/16 |
| Procedural painInjury, poisoning and procedural complications | 0/16 | 1/13 | 0/10 | 2/8 | 1/7 | 0/16 |
| CSF white blood cell count increasedInvestigations | 0/16 | 1/13 | 0/10 | 2/8 | 0/7 | 2/16 |
| CSF protein increasedInvestigations | 0/16 | 2/13 | 1/10 | 2/8 | 0/7 | 1/16 |
| NauseaGastrointestinal disorders | 0/16 | 1/13 | 0/10 | 2/8 | 0/7 | 0/16 |
| FatigueGeneral disorders | 2/16 | 2/13 | 0/10 | 1/8 | 1/7 | 2/16 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/16 | 2/13 | 0/10 | 0/8 | 0/7 | 0/16 |
| Age, Continuous(years) | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 | Total |
|---|---|---|---|---|---|---|---|
| Period 1 | 45.5 ± 7.4 | 47.8 ± 9.2 | 43.9 ± 8.6 | 49.6 ± 5.3 | — | — | 46.5 ± 7.9 |
| Period 2 | — | — | — | — | 45.6 ± 8.3 | 47.8 ± 8.3 | 47.1 ± 8.2 |
| Sex: Female, Male(Participants) | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 | Total |
|---|---|---|---|---|---|---|---|
| Period 1 — Female | 6 | 6 | 3 | 3 | — | — | 18 |
| Period 1 — Male | 10 | 7 | 7 | 5 | — | — | 29 |
| Period 2 — Female | — | — | — | — | 2 | 5 | 7 |
| Period 2 — Male | — | — | — | — | 5 | 11 | 16 |
| Ethnicity (NIH/OMB)(Participants) | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 | Total |
|---|---|---|---|---|---|---|---|
| Period 1 — Hispanic or Latino | 1 | 0 | 0 | 0 | — | — | 1 |
| Period 1 — Not Hispanic or Latino | 15 | 13 | 10 | 8 | — | — | 46 |
| Period 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 2 — Hispanic or Latino | — | — | — | — | 1 | 0 | 1 |
| Period 2 — Not Hispanic or Latino | — | — | — | — | 6 | 16 | 22 |
| Period 2 — Unknown or Not Reported | — | — | — | — | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SAD: Pooled Placebo | SAD: 30mg WVE-003 | SAD: 60mg WVE-003 | SAD: 90mg WVE-003 | MD: Placebo | MD: 30mg WVE-003 | Total |
|---|---|---|---|---|---|---|---|
| Period 1 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 1 — Asian | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 1 — Black or African American | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 1 — White | 16 | 13 | 10 | 8 | — | — | 47 |
| Period 1 — More than one race | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 | — | — | 0 |
| Period 2 — American Indian or Alaska Native | — | — | — | — | 0 | 0 | 0 |
| Period 2 — Asian | — | — | — | — | 0 | 0 | 0 |
| Period 2 — Native Hawaiian or Other Pacific Islander | — | — | — | — | 0 | 0 | 0 |
| Period 2 — Black or African American | — | — | — | — | 7 | 16 | 23 |
| Period 2 — White | — | — | — | — | 0 | 0 | 0 |
| Period 2 — More than one race | — | — | — | — | 0 | 0 | 0 |
| Period 2 — Unknown or Not Reported | — | — | — | — | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in May 2024, 32 months.
Results were first posted in Aug 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wave Life Sciences USA, Inc.